[[{“value”:”
Guardant Health’s Shield, a liquid biopsy that screens for colorectal cancer by analyzing a patient blood sample, will compete against stool-based tests already established in the market. Shield could also face new competition from other liquid biopsy companies.
The post With FDA Nod for Colorectal Cancer Screening, How Much Market Share Can Guardant’s Blood Test Get? appeared first on MedCity News.
“}]]
